Pulse Biosciences Hires Liane Teplitsky as COO

Why It Matters

Teplitsky’s appointment gives Pulse seasoned cardiovascular leadership to fast‑track FDA clearance and market entry, positioning the firm to capture growth in the expanding PFA market for atrial fibrillation.

Key Takeaways

• Liane Teplitsky named COO to steer Pulse's PFA device rollout
• Pulse reallocates R&D to nPulse Cardiac Catheter, cuts surgical clamp program
• First‑in‑human trial enrolls 150 European patients, U.S. trial begins
• Teplitsky brings Abbott, Zimmer Biomet, and robotics experience to Pulse
• FDA cleared pivotal trial for 215 atrial fibrillation patients

Pulse Analysis

The cardiac electrophysiology landscape is being reshaped by pulsed‑field ablation, a non‑thermal technology that promises faster, safer isolation of pulmonary veins compared with traditional radiofrequency or cryoablation. Pulse Biosciences’ nPulse Cardiac Catheter is one of the few devices positioned to deliver this capability through a percutaneous soft‑tissue approach. Early European data on 150 patients showed high acute success rates and minimal collateral damage, fueling investor confidence and prompting the company to allocate the bulk of its R&D budget to the catheter while shelving a surgical clamp program.

Bringing a depth of cardiovascular and robotics expertise, Liane Teplitsky joins Pulse as chief operating officer after senior roles at Abbott, Zimmer Biomet and as CEO of Artedrone, a stroke‑treatment robotics firm. Her track record of guiding products from concept through regulatory approval is expected to streamline Pulse’s clinical, quality and commercial pipelines. The appointment coincides with a broader C‑suite overhaul that added CEO Paul LaViolette and CFO Jon Skinner, signaling a decisive pivot toward accelerated market entry for the nPulse system.

The FDA cleared a pivotal trial earlier this year, enrolling up to 215 drug‑resistant, symptomatic paroxysmal atrial fibrillation patients across the United States and Europe. Successful completion could unlock a fast‑track pathway and position Pulse to compete with established players such as Boston Scientific and Medtronic in a market projected to exceed $5 billion by 2030. With Teplitsky steering regulatory filings and commercial strategy, the company aims to launch the nPulse catheter within the next 12‑18 months, potentially reshaping treatment standards for atrial fibrillation.